India’s Contract Manufacturing: Prospects And Pains
This article was originally published in PharmAsia News
Is the general uptrend in India's contract manufacturing segment sustainable, despite some sentiment-dampening run-ins with regulators over compliance concerns?
You may also be interested in...
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Pharma appears to be treading carefully when it comes to research preprints but COVID-19 has spotlighted the role of these pre-peer-reviewed papers during public health emergencies.